Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2021

01-11-2021 | Metastasis | Original Article

DEAD-Box Helicase 3 X-Linked Promotes Metastasis by Inducing Epithelial-Mesenchymal Transition via p62/Sequestosome-1

Authors: Ying Zheng, Bing Xu, Yitong Zhao, Suzhen Yang, Shuhui Wang, Lin Ma, Lei Dong

Published in: Digestive Diseases and Sciences | Issue 11/2021

Login to get access

Abstract

Background

DEAD-Box Helicase 3 X-Linked (DDX3X) is a member of the DEAD-box helicases that play a crucial role in RNA metabolism. Although DDX3X has been shown to contribute to tumorigenesis, the detailed mechanisms by which DDX3X functions in pancreatic ductal adenocarcinoma (PDAC) biogenesis remain poorly understood.

Aims

The goal of the present study was to elucidate the molecular mechanisms by which DDX3X contributes to tumorigenesis in PDAC.

Methods

Kaplan–Meier curves, the log-rank test, t test and Cox regression were used to analyze the relationship between DDX3X expression and the clinicopathological features of PDAC patients. DDX3X and p62 expression in human PDAC tissues was analyzed by immunohistochemistry. Monolayer scratch healing assays, cell migration assays and nude mouse lung metastasis models were used to evaluate the effect of DDX3X on metastasis in vitro and in vivo. Western blot analysis was used to assess the expression of proteins in the signaling pathway.

Results

We authenticated high DDX3X expression was associated with a poor prognosis in PDAC. The loss of DDX3X attenuated the migratory capacity of PDAC cells in vitro and in vivo. DDX3X was shown to facilitate epithelial-mesenchymal transition (EMT) and the phosphorylation of p65 and eIF2α. Moreover, DDX3X displayed oncogenic activity by promoting p62 accumulation.

Conclusions

Our results demonstrated that DDX3X activates NF-κB and promotes metastasis by inducing EMT via p62.
Appendix
Available only for authorised users
Literature
1.
go back to reference Soto-Rifo R, Ohlmann T. The role of the DEAD-box RNA helicase DDX3 in mRNA metabolism. Wiley Interdiscip Rev RNA. 2013;4:369–385.CrossRef Soto-Rifo R, Ohlmann T. The role of the DEAD-box RNA helicase DDX3 in mRNA metabolism. Wiley Interdiscip Rev RNA. 2013;4:369–385.CrossRef
2.
go back to reference Kerr CL, Bol GM, Vesuna F, et al. Targeting RNA helicase DDX3 in stem cell maintenance and teratoma formation. Genes Cancer. 2019;10:11–20.CrossRef Kerr CL, Bol GM, Vesuna F, et al. Targeting RNA helicase DDX3 in stem cell maintenance and teratoma formation. Genes Cancer. 2019;10:11–20.CrossRef
3.
go back to reference Samir P, Kesavardhana S, Patmore DM, et al. DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome. Nature. 2019;573:590–594.CrossRef Samir P, Kesavardhana S, Patmore DM, et al. DDX3X acts as a live-or-die checkpoint in stressed cells by regulating NLRP3 inflammasome. Nature. 2019;573:590–594.CrossRef
4.
go back to reference Chao CH, Chen CM, Cheng PL, et al. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer Res. 2006;66:6579–6588.CrossRef Chao CH, Chen CM, Cheng PL, et al. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor. Cancer Res. 2006;66:6579–6588.CrossRef
5.
go back to reference Vellky JE, Ricke EA, Huang W, et al. Expression and localization of DDX3 in prostate cancer progression and metastasis. Am J Pathol. 2019;189:1256–1267.CrossRef Vellky JE, Ricke EA, Huang W, et al. Expression and localization of DDX3 in prostate cancer progression and metastasis. Am J Pathol. 2019;189:1256–1267.CrossRef
6.
go back to reference Botlagunta M, Vesuna F, Mironchik Y, et al. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene. 2008;27:3912–3922.CrossRef Botlagunta M, Vesuna F, Mironchik Y, et al. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene. 2008;27:3912–3922.CrossRef
7.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.CrossRef
8.
go back to reference Ling J, Kang Y, Zhao R, et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:105–120.CrossRef Ling J, Kang Y, Zhao R, et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:105–120.CrossRef
9.
go back to reference Yang H, Cui J, Shi J, et al. Endoplasmic reticulum stress participates in inflammation-accelerated, lipid-mediated injury of human glomerular mesangial cells. Nephrology (Carlton, Vic). 2017;22:234–242.CrossRef Yang H, Cui J, Shi J, et al. Endoplasmic reticulum stress participates in inflammation-accelerated, lipid-mediated injury of human glomerular mesangial cells. Nephrology (Carlton, Vic). 2017;22:234–242.CrossRef
10.
go back to reference Paul S, Traver MK, Kashyap AK, et al. T cell receptor signals to NF-kappaB are transmitted by a cytosolic p62-Bcl10-Malt1-IKK signalosome. Sci Signal. 2014;7:45.CrossRef Paul S, Traver MK, Kashyap AK, et al. T cell receptor signals to NF-kappaB are transmitted by a cytosolic p62-Bcl10-Malt1-IKK signalosome. Sci Signal. 2014;7:45.CrossRef
11.
go back to reference Zotti T, Scudiero I, Settembre P, et al. TRAF6-mediated ubiquitination of NEMO requires p62/sequestosome-1. Mol Immunol. 2014;58:27–31.CrossRef Zotti T, Scudiero I, Settembre P, et al. TRAF6-mediated ubiquitination of NEMO requires p62/sequestosome-1. Mol Immunol. 2014;58:27–31.CrossRef
12.
go back to reference Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell. 2017;168:692–706.CrossRef Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell. 2017;168:692–706.CrossRef
13.
go back to reference Rodriguez-Aznar E, Wiesmüller L, Sainz B Jr, et al. EMT and stemness-key players in pancreatic cancer stem cells. Cancers. 2019;11:1136.CrossRef Rodriguez-Aznar E, Wiesmüller L, Sainz B Jr, et al. EMT and stemness-key players in pancreatic cancer stem cells. Cancers. 2019;11:1136.CrossRef
14.
go back to reference Ayres Pereira M, Chio IIC. Metastasis in pancreatic ductal adenocarcinoma: current standing and methodologies. Genes. 2019;11:6.CrossRef Ayres Pereira M, Chio IIC. Metastasis in pancreatic ductal adenocarcinoma: current standing and methodologies. Genes. 2019;11:6.CrossRef
15.
go back to reference Umemura A, He F, Taniguchi K, et al. p62, Upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell. 2016;29:935–948.CrossRef Umemura A, He F, Taniguchi K, et al. p62, Upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell. 2016;29:935–948.CrossRef
16.
go back to reference Iwadate R, Inoue J, Tsuda H, et al. High expression of p62 protein is associated with poor prognosis and aggressive phenotypes in endometrial cancer. Am J Pathol. 2015;185:2523–2533.CrossRef Iwadate R, Inoue J, Tsuda H, et al. High expression of p62 protein is associated with poor prognosis and aggressive phenotypes in endometrial cancer. Am J Pathol. 2015;185:2523–2533.CrossRef
17.
go back to reference Inami Y, Waguri S, Sakamoto A, et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol. 2011;193:275–284.CrossRef Inami Y, Waguri S, Sakamoto A, et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol. 2011;193:275–284.CrossRef
18.
go back to reference Mathew R, Karp CM, Beaudoin B, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009;137:1062–1075.CrossRef Mathew R, Karp CM, Beaudoin B, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009;137:1062–1075.CrossRef
19.
go back to reference Duran A, Linares JF, Galvez AS, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell. 2008;13:343–354.CrossRef Duran A, Linares JF, Galvez AS, et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell. 2008;13:343–354.CrossRef
20.
go back to reference Guttridge DC, Albanese C, Reuther JY, et al. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785–5799.CrossRef Guttridge DC, Albanese C, Reuther JY, et al. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785–5799.CrossRef
21.
go back to reference Kang YK, Putluri N, Maity S, et al. CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-α-Gabpa and stress-induced adaptive responses via NF-κB-cMYC. PLoS Genet. 2015;11:e1005116.CrossRef Kang YK, Putluri N, Maity S, et al. CAPER is vital for energy and redox homeostasis by integrating glucose-induced mitochondrial functions via ERR-α-Gabpa and stress-induced adaptive responses via NF-κB-cMYC. PLoS Genet. 2015;11:e1005116.CrossRef
Metadata
Title
DEAD-Box Helicase 3 X-Linked Promotes Metastasis by Inducing Epithelial-Mesenchymal Transition via p62/Sequestosome-1
Authors
Ying Zheng
Bing Xu
Yitong Zhao
Suzhen Yang
Shuhui Wang
Lin Ma
Lei Dong
Publication date
01-11-2021
Publisher
Springer US
Keyword
Metastasis
Published in
Digestive Diseases and Sciences / Issue 11/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06735-z

Other articles of this Issue 11/2021

Digestive Diseases and Sciences 11/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine